The essentials—measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions
American Journal of Clinical Pathology · 06.07.2026 · 166 (1)
DOI: 10.1093/ajcp/aqag079 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 09.07.2026. Verfasst von Savanah D Gisriel und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, United States. Hauptthemen laut MEDLINE: Neoplasm, Residual, Hematologic Neoplasms. Die Arbeit nennt 65 Literaturangaben.
Abstract (Originalsprache)
Objectives
Measurable residual disease (MRD) analysis, also known as minimal residual disease analysis, has become an essential component of routine clinical management in many hematopoietic neoplasms. Measurable residual disease status in the absence of morphologic disease holds prognostic value and can acutely affect treatment decisions.
Methods
Measurable residual disease monitoring is described in acute leukemia, multiple myeloma, and chronic lymphocytic leukemia. We discuss the approach to MRD assessment of these hematologic neoplasms using flow cytometry and molecular techniques.
Results
The appropriate use of available ancillary techniques is crucial to assess patients for MRD. Interpreting these results in the appropriate clinical context is challenging and often requires expertise. Incorporating the results into disease management is critical for improved outcomes.
Conclusions
Consensus guidelines on MRD assessment in hematopoietic neoplasms continue to evolve. Further, emerging technologies and laboratory availability are important practical considerations for pathologists who are implementing MRD analysis. From this review, pathologists can gain an anecdotal perspective on the application and interpretation of advanced studies to assess the MRD status of patients with hematopoietic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI, United States.
- Departments of Pathology and Laboratory Medicine, Yale School of Medicine, New Haven, CT, United States.
ORCID-Profile: Savanah D Gisriel, Alexa Siddon
Zitieren
APA
Gisriel, S. D., & Siddon, A. (2026). The essentials—measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions. American Journal of Clinical Pathology, 166(1). https://doi.org/10.1093/ajcp/aqag079
Vancouver
Gisriel SD, Siddon A. The essentials—measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions. American Journal of Clinical Pathology. 2026;166(1). doi:10.1093/ajcp/aqag079
BibTeX
@article{Gisriel2026,
author = {Gisriel, Savanah D and Siddon, Alexa},
title = {The essentials—measurable residual disease in hematopoietic neoplasms: current testing landscape and future directions},
journal = {American Journal of Clinical Pathology},
year = {2026},
volume = {166},
number = {1},
doi = {10.1093/ajcp/aqag079}
}
EUVIMED